ArticleBMC cardiovascular disorders2026
The association between modified cardiometabolic index and cardiovascular disease risk in adults with early cardiovascular-kidney-metabolic syndrome: a prospective cohort study.
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nationwide prospective cohort study in China: the impact of cumulative modified cardiometabolic index on cardiovascular disease incidence.Frontiers in cardiovascular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundCardiovascular-Kidney-Metabolic (CKM) syndrome highlights the interconnections between cardiovascular disease (CVD), chronic kidney disease (CKD), and type 2 diabetes (DM). The modified Cardiometabolic Index (MCMI), which integrates measures of insulin resistance, abdominal obesity, dyslipidemia, and blood glucose, may better reflect metabolic and cardiovascular risk than the original index. However, its association with cardiovascular and cerebrovascular disease risk in individuals with early CKM syndrome (stages 0–3) remains unclear.
methodsThis longitudinal study utilized data from 6,953 participants in stages 0–3 of CKM syndrome from the China Health and Retirement Longitudinal Study (CHARLS). The MCMI was calculated at baseline. Participants were followed for a median of 7.8 years to track the incidence of cardiovascular disease, heart disease, and stroke. Cox proportional hazards models were employed to analyze the association between MCMI levels and the risk of these outcomes, adjusting for various sociodemographic, lifestyle, and clinical factors.
resultsDuring follow-up, 1,534 participants developed CVD. Higher MCMI levels were significantly associated with increased risks of overall CVD and stroke. In fully adjusted models, each unit increase in MCMI was associated with a 21% and 47% higher risk of CVD and stroke, respectively. Participants in the highest MCMI quartile had a 55% higher risk of CVD and a 2.55-fold higher risk of stroke compared to the lowest quartile. The association with heart disease was weaker and became non-significant after full adjustment. Dose-response analyses revealed nonlinear relationships for CVD and stroke. Subgroup and sensitivity analyses confirmed the robustness of these findings.
conclusionMCMI is independently associated with an increased risk of overall CVD and stroke in individuals with early-stage CKM syndrome; its association with heart disease is weak, with statistical significance only observed in the highest MCMI quartile and partially attenuated by adjustment for traditional metabolic and cardiovascular risk factors. MCMI serves as a practical indicator for cardiovascular risk stratification, offering a valuable tool for early prevention and management of CVD and stroke in the preclinical phases of CKM syndrome.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.